NEW YORK, May 29, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) announced it has entered into a research collaboration with the University of Southampton, a leading biomedical and clinical research institution located in the United Kingdom. The collaboration will partner Protea's proprietary direct molecular imaging technology and capabilities with a team of Alzheimer's researchers at the University of Southampton, to study the molecular mechanisms of the aged brain, in order to identify markers that may indicate risk of developing Alzheimer's disease.
The announcement was made today at the Third Annual Marcum Microcap Conference held in New York City.
Roxana Carare M.D., Ph.D., leading the Carare Research Group at the University of Southampton, U.K., Matthew Powell Ph.D. and Greg Kilby Ph.D. of Protea Biosciences, will serve as the Principal Investigators for this collaboration.
Roxana Carare, M.D., Ph.D., who leads the cerebrovascular ageing research group at the University of Southampton, commented, "We are delighted that the novel molecular techniques from Protea Biosciences will be applied to brain tissue. We anticipate that novel biomarkers for the early detection of Alzheimer's disease or markers that identify the risk factors for developing Alzheimer's disease will be discovered and make significant progress in the field of biomedical research."
Steve Turner, Protea's Chief Executive Officer stated, "It has been a strategic goal of Protea to apply our direct molecular imaging technology and expertise to the field of neurodegenerative disease, and we are pleased to be doing so with the University of Southampton. We believe that the capabilities of our technology to directly identify and image hundreds of molecules produced by cells from a single analysis has the potential to identify new biomarkers and therapeutic points of intervention for use in the development of new Alzheimer's treatments and patient management tools."
About Protea Biosciences Group, Inc.
Protea Biosciences (OTCQB:PRGB) is a commercial stage molecular information company, focused on meeting the needs of the pharmaceutical, biotechnology, agriculture, chemical and other industries with innovative technologies, software and services. Protea's proprietary technology, LAESI® (Laser Ablation Electrospray Ionization), is used with mass spectrometry to detect the presence of up to, and over, one thousand distinct molecules from a single analysis of samples that can include tissues, cells, fluids, agricultural specimens and other sample types. Using proprietary software (ProteaPlotTM), the location of each distinct molecule in a respective sample can be displayed, enabling direct molecular imaging. The LAESI DP-1000, an integrated system that combines LAESI and ProteaPlot, is marketed to a wide array of researchers for numerous applications. Protea maintains its own laboratory facility where it performs services using LAESI and complementary technologies for a wide array of customers to support preclinical pharmaceutical R&D, biomarker discovery and other applications. Protea also collaborates with researchers to apply its technologies and expertise to generate new discoveries and intellectual property.
Forward-Looking Statements
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the company's control. It is possible that the company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the company and its business, including factors that potentially could materially affect the company's financial results, are contained in the company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
https://proteabio.com/investors
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.